Summit Tx Capital, L.P. Supernus Pharmaceuticals, Inc. Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
A detailed history of Summit Tx Capital, L.P. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 35,490 shares of SUPN stock, worth $1.12 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
35,490Holding current value
$1.12 Million% of portfolio
0.05%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
305Shares Held
60.8MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$328 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$194 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$164 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$91.5 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$85.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.69B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...